CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis
NCT ID: NCT04205396
Last Updated: 2022-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
87 participants
INTERVENTIONAL
2020-02-10
2022-03-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Caretakers that meet eligibility will complete baseline assessments in person, or if necessary, over the phone and be randomized to be in one of three arms of this study. Materials specific to each study arm will be mailed to the caretakers home along with instructions. Overall, the study will take approximately 2 months and a qualitative interview will also be completed around 3-6 months post-baseline.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nurse Assisted Post-discharge Intervention in Decompensated Cirrhosis
NCT04158986
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
NCT06223893
Mindfulness and Support Group to Improve Patient and Caregiver Burden in Cirrhosis
NCT02944643
Health IT Generated PROs to Improve Outcomes in Cirrhosis
NCT03564626
Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial
NCT04149223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Written emotional disclosure
Written emotional disclosure
Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
Resilience training
Resilience training
Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
Control arm
No treatment
Participants will complete baseline and outcome assessments and no intervention will be conducted.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Written emotional disclosure
Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
Resilience training
Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
No treatment
Participants will complete baseline and outcome assessments and no intervention will be conducted.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Child-Turcotte Pugh (CTP) Class A/B/C cirrhosis with an all cause hospitalization within the previous 30 days.
2. CTP Class B or C cirrhosis with one of the following within the prior 6 months from the date of enrollment:
1. Ascites (requiring paracentesis or diuretics)
2. Overt Hepatic Encephalopathy (requiring lactulose or rifaximin/flagyl/neomycin)
3. Spontaneous Bacterial Peritonitis (SBP)
4. Hepatic Hydrothorax (requiring diuretics or thoracentesis)
5. Variceal Bleed (with 1 or more recurrences)
3. Hepatocellular Carcinoma (HCC)
1. Any Barcelona Clinic Liver Cancer (BCLC) Stage with CTP Class B or C
2. BCLC Stage C or D with CTP Class A
Exclusion Criteria
* Unable or unwilling to provide verbal consent
* Severe cognitive impairment
* Caregiver is participating in another interventional study
* Caregiver has used a personal diary within the past 12 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elliot B. Tapper
Assistant Professor of Internal Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elliot Tapper, MD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tapper EB, Saleh ZM, Lizza S, Chen X, Nikirk S, Serper M. CAREGIVER Randomized Trial of Two Mindfulness Methods to Improve the Burden and Distress of Caring for Persons with Cirrhosis. Dig Dis Sci. 2023 Sep;68(9):3625-3633. doi: 10.1007/s10620-023-08042-9. Epub 2023 Jul 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUM00167479
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.